



## PharmaMar group announces 2017 earnings results

- **Revenues totalled €179.4 million.**
- **The Oncology segment reported €2.9 million in EBITDA.**
- **Consumer Chemicals net sales increased by 3.4%.**
- **The Group's adjusted EBITDA improved by 33%.**

**Madrid, 28 February 2018:** The Pharma Mar group (MSE: PHM) reported €179.4 million in total revenues in 2017 (€181 million in 2016).

Net sales of Yondelis<sup>®</sup> continued to be robust in 2017 and it retained a leading market share for the treatment of soft tissue sarcoma despite price pressure. As a result, Yondelis<sup>®</sup> net sales totalled €84.6 million in 2017 (vs. €88.2 million in 2016). Licensing and co-development revenues in Oncology increased by 11% in 2017 to €12.3 million partly because of the new licensing contracts for Zepsyre<sup>®</sup>, signed with Specialised Therapeutics Asia PTE., Ltd. for the territories of Australia and New Zealand, and with Boryung Pharmaceutical for the territory of South Korea. PharmaMar also signed a licensing deal for Aplidin<sup>®</sup> with Eip Eczacibasi Ilac Pazarlama A.S. for the territory of Turkey.

The Consumer Chemicals area reported €72 million in revenues in 2017, a 3.4% increase year-on-year.

The PharmaMar group ended 2017 with adjusted EBITDA of €-7.4 million, a 33% improvement on 2016. This improvement can be attributed partly to the Oncology segment, which contributed €2.9 million in positive EBITDA due, amongst factors, to efficient management of marketing expenses.

As a result, the Group reported a net attributable loss of -€26.7 million in 2017, compared with -€24 million net profit in 2016.



PharmaMar management will host an investment-community conference call at 8:00 a.m. ET on Thursday March 1, 2018 to discuss the financial results and to provide a corporate update.

Investors who wish to participate in the conference call may do so by dialling 877-407-3102 for U.S. and Canadian callers or 201-493-6790 for international callers.

A webcast replay will be available on the PharmaMar website for 30 days following the call by visiting the Events Calendar page of the company's website at [www.pharmamar.com](http://www.pharmamar.com).

#### **About PharmaMar**

PharmaMar, a Madrid-based biopharmaceutical company, is a world leader in discovering, developing and marketing anti-tumour drugs obtained from the sea. PharmaMar has a pipeline of pre-clinical candidates and a major R&D programme. The company develops and markets YONDELIS® in Europe and has three other compounds in clinical development for treating solid and haematological tumours: plitidepsin, PM1183 and PM184. PharmaMar is a global biopharmaceutical company with a presence in Germany, Italy, France, Switzerland, Austria, the United Kingdom, Austria, Belgium and the USA. PharmaMar also has a majority stake in other companies: GENOMICA, a leading molecular diagnostics company; Sylentis, focused on developing therapeutic applications of gene silencing (RNAi); and two chemical companies: Zelnova Zeltia and Xylazel. For more information, visit our website:

#### **Important note**

This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe for shares of the company. Moreover, no reliance should be placed upon this document or its distribution for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the Company.

#### **Further information from:**

Alfonso Ortín – Communications Director [aortin@pharmamar.com](mailto:aortin@pharmamar.com) Mobile: + 34609493127  
Paula Fernández – Media Relations Manager [pfalarcon@pharmamar.com](mailto:pfalarcon@pharmamar.com)

Mobile: +34 638796215

Phone: +34 918466000

José Luis Moreno Martínez-Losa – Head of Investor Relations and Capital Markets  
[investorrelations@pharmamar.com](mailto:investorrelations@pharmamar.com)

Phone: +34 914444500

For more information, visit our website: [www.pharmamar.com](http://www.pharmamar.com)

###